The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
|Videos|April 30, 2021
The Evolving Diagnostic Criteria for Multiple Sclerosis
Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Hesham Abboud, MD, PhD
Assistant Professor of Neurology, Case Western Reserve University School of Medicine; Director, Multiple Sclerosis and Neuroimmunology Program, Staff Neurologist, Parkinson’s and Movement Disorders Center, University Hospitals, Cleveland Medical Center - Rana K. Zabad, MD, FAAN
Professor, Department of Neurological Sciences, Chief, Multiple Sclerosis/Neuroimmunology Section, Program Director, Multiple Sclerosis Fellowship, University of Nebraska Medical Center
Key Learning Objectives
- Virtual patient visits during COVID-19 when diagnosing MS
- Review of the revised 2017 McDonald criteria
- Determining MS mimickers
- The future of diagnosing MS
Resources
Advertisement
Related to this article
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.
Here's some of what is coming soon to NeurologyLive® this week.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
Topline Phase 2 ADDRESS-LC Data Show Subgroup Benefit for Bezisterim in Long COVID
3
Previewing Advancements in Hypersomnia Diagnosis and Treatment
4
Brain Network Changes Appear Decades Before Motor Symptoms in Huntington Disease
5